In­cyte grabs con­trol of a can­cer drug from Calithera’s pipeline for $53M up front

In­cyte $IN­CY has swooped in and gained con­trol of Calithera’s $CALA num­ber #2 can­cer drug with a $53 mil­lion cash pay­day.

The col­lab­o­ra­tion gives In­cyte the lead on CB-1158, a ther­a­py de­signed to in­hib­it arginase, an en­zyme that reins in T-cell and nat­ur­al killer cell ac­ti­va­tion in tu­mors. The plan is to test it as a monother­a­py but al­so in com­bi­na­tion with im­muno-on­col­o­gy drugs – in par­tic­u­lar an an­ti-PD-1 ther­a­py – to test its po­ten­tial for fu­ture com­bos.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.